Preview

Пульмонология

Расширенный поиск

Ингаляционные кортикостероиды при стабильной хронической обструктивной болезни легких: эволюция взглядов

https://doi.org/10.18093/0869-0189-2008-0-5-108-112

Полный текст:

Об авторе

Е. И. Шмелев
Отдел пульмонологии ГУ ЦНИИТ РАМН
Россия
Москва


Список литературы

1. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–1823.

2. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.

3. Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive lung disease. N. Engl. J. Med. 2000; 343: 1902–1909.

4. Paggiaro P.L., Dahle R., Bakran I. et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773–780.

5. Spencer S., Calverley P.M.A., Burge S., Jones P.W. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 122–128.

6. Baranuik J.N., Ali M., Brody D. et al. Glucocorticoids induce β2-andrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 704–710.

7. Usmani O.S., Maneechotesuwan K., Adcock I.M. et al. Glucocorticoid receptor activation following inhaled fluticasone & salmeterol. Am. J. Respir. Crit. Care Med. 2002; 165 (suppl. 8): A616.

8. Calverley P.M.A., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

9. Jarad N.A., Wedzicha J.A., Burge P.S., Calverley P.M. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir. Med. 1999; 93: 161–166.

10. Vincken W., van Noord J.A., Greefhorst A.P. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.

11. Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.

12. Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 472–478.

13. Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007; 62: 938–943.

14. Jeffery P. Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma. Expert. Opin. Invest. Drugs 2005; 14: 619–632.

15. Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A metaanalysis. Thorax 2006; 61: 854–862.

16. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.


Для цитирования:


Шмелев Е.И. Ингаляционные кортикостероиды при стабильной хронической обструктивной болезни легких: эволюция взглядов. Пульмонология. 2008;(5):108-112. https://doi.org/10.18093/0869-0189-2008-0-5-108-112

For citation:


Shmelev E.I. Inhaled corticosteroids in stable chronic obstructive pulmonary disease: an evolution of opinions. PULMONOLOGIYA. 2008;(5):108-112. (In Russ.) https://doi.org/10.18093/0869-0189-2008-0-5-108-112

Просмотров: 20


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)